Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Chemizon has announced that it has signed an agreement with Array BioPharma to provide Array with various medicinal chemistry services including chemical synthesis and new route research. Chemizon’s ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

BOULDER, Colo., June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI™ capsules in combination with ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

* Point72 Asset Management L.P reports 5.4 percent passive stake in Array Biopharma Inc as of September 11, 2017 - SEC filing‍ Source text: Further company coverage: ...

Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...